RNA干扰疗法的业务。 - Suppr

Suppr

超能文献

The business of RNAi therapeutics.

作者信息

Haussecker Dirk

机构信息

Department of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA.

出版信息

Hum Gene Ther. 2008 May;19(5):451-62. doi: 10.1089/hum.2008.007.

DOI:10.1089/hum.2008.007

PMID:18435603

Abstract

摘要

相似文献

The business of RNAi therapeutics.

Hum Gene Ther. 2008 May;19(5):451-62. doi: 10.1089/hum.2008.007.

UK industry consolidation is slow despite big merger.

Nat Biotechnol. 2003 Mar;21(3):215. doi: 10.1038/nbt0303-215.

What's fueling the biotech engine?

Nat Biotechnol. 2007 Oct;25(10):1097-104. doi: 10.1038/nbt1007-1097.

Unlocking the money-making potential of RNAi.

Nat Biotechnol. 2003 Dec;21(12):1441-6. doi: 10.1038/nbt1203-1441.

Gaining medical momentum.

Nature. 2004 Jun 3;429(6991 Suppl):19-23. doi: 10.1038/429a19a.

Interview with Marc Ferrer, Ph.D.. Interview by Vicki Glaser.

Assay Drug Dev Technol. 2010 Jun;8(3):263-7. doi: 10.1089/adt.2010.0803.pr.

Building for an exit (or not).

Nat Biotechnol. 2008 Sep;26(9):971-3. doi: 10.1038/bioe.2008.8.

siRNAs: applications in functional genomics and potential as therapeutics.

Nat Rev Drug Discov. 2004 Apr;3(4):318-29. doi: 10.1038/nrd1345.

The shape of European business in 2003.

Med Device Technol. 2002 Dec;13(10):8-10.

Pharmas partner in venture seeking drug discovery tools.

Nat Biotechnol. 2008 Sep;26(9):960-1. doi: 10.1038/nbt0908-960.

引用本文的文献

The long transcript of lncRNA TMPO-AS1 promotes bone metastases of prostate cancer by regulating the CSNK2A1/DDX3X complex in Wnt/β-catenin signaling.

Cell Death Discov. 2023 Aug 5;9(1):287. doi: 10.1038/s41420-023-01585-w.

Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles.

Mol Ther Nucleic Acids. 2021 Aug 8;25:524-535. doi: 10.1016/j.omtn.2021.07.021. eCollection 2021 Sep 3.

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143. doi: 10.1016/j.omtn.2017.06.005. Epub 2017 Jun 12.

Nano-based delivery of RNAi in cancer therapy.

Mol Cancer. 2017 Jul 28;16(1):134. doi: 10.1186/s12943-017-0683-y.

'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.

Br J Pharmacol. 2017 Dec;174(24):4684-4700. doi: 10.1111/bph.13958. Epub 2017 Aug 23.

High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA.

AAPS J. 2015 Nov;17(6):1475-82. doi: 10.1208/s12248-015-9812-y. Epub 2015 Aug 19.

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.

Int J Nanomedicine. 2014 May 10;9:2271-85. doi: 10.2147/IJN.S57449. eCollection 2014.

U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo.

Mol Ther Nucleic Acids. 2013 May 14;2(5):e92. doi: 10.1038/mtna.2013.24.

The Business of RNAi Therapeutics in 2012.

Mol Ther Nucleic Acids. 2012 Feb 7;1(2):e8. doi: 10.1038/mtna.2011.9.

Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.

Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):494-502. doi: 10.1167/iovs.12-10528.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The business of RNAi therapeutics.

Hum Gene Ther. 2008 May;19(5):451-62. doi: 10.1089/hum.2008.007.

UK industry consolidation is slow despite big merger.

Nat Biotechnol. 2003 Mar;21(3):215. doi: 10.1038/nbt0303-215.

What's fueling the biotech engine?

Nat Biotechnol. 2007 Oct;25(10):1097-104. doi: 10.1038/nbt1007-1097.

Unlocking the money-making potential of RNAi.

Nat Biotechnol. 2003 Dec;21(12):1441-6. doi: 10.1038/nbt1203-1441.

Gaining medical momentum.

Nature. 2004 Jun 3;429(6991 Suppl):19-23. doi: 10.1038/429a19a.

Interview with Marc Ferrer, Ph.D.. Interview by Vicki Glaser.

Assay Drug Dev Technol. 2010 Jun;8(3):263-7. doi: 10.1089/adt.2010.0803.pr.

Building for an exit (or not).

Nat Biotechnol. 2008 Sep;26(9):971-3. doi: 10.1038/bioe.2008.8.

siRNAs: applications in functional genomics and potential as therapeutics.

Nat Rev Drug Discov. 2004 Apr;3(4):318-29. doi: 10.1038/nrd1345.

The shape of European business in 2003.

Med Device Technol. 2002 Dec;13(10):8-10.

Pharmas partner in venture seeking drug discovery tools.

Nat Biotechnol. 2008 Sep;26(9):960-1. doi: 10.1038/nbt0908-960.

引用本文的文献

The long transcript of lncRNA TMPO-AS1 promotes bone metastases of prostate cancer by regulating the CSNK2A1/DDX3X complex in Wnt/β-catenin signaling.

Cell Death Discov. 2023 Aug 5;9(1):287. doi: 10.1038/s41420-023-01585-w.

Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles.

Mol Ther Nucleic Acids. 2021 Aug 8;25:524-535. doi: 10.1016/j.omtn.2021.07.021. eCollection 2021 Sep 3.

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143. doi: 10.1016/j.omtn.2017.06.005. Epub 2017 Jun 12.

Nano-based delivery of RNAi in cancer therapy.

Mol Cancer. 2017 Jul 28;16(1):134. doi: 10.1186/s12943-017-0683-y.

'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.

Br J Pharmacol. 2017 Dec;174(24):4684-4700. doi: 10.1111/bph.13958. Epub 2017 Aug 23.

High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA.

AAPS J. 2015 Nov;17(6):1475-82. doi: 10.1208/s12248-015-9812-y. Epub 2015 Aug 19.

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.

Int J Nanomedicine. 2014 May 10;9:2271-85. doi: 10.2147/IJN.S57449. eCollection 2014.

U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo.

Mol Ther Nucleic Acids. 2013 May 14;2(5):e92. doi: 10.1038/mtna.2013.24.

The Business of RNAi Therapeutics in 2012.

Mol Ther Nucleic Acids. 2012 Feb 7;1(2):e8. doi: 10.1038/mtna.2011.9.

Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.

Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):494-502. doi: 10.1167/iovs.12-10528.